Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemzar and Alimta in recurrent ovarian or peritoneal cancer
NCT00055432Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in ovarian cancer and primary peritoneal cancer (PPC), sponsored by Eli Lilly and Company. Primary endpoint: Beneficial effects of the combination. Status: terminated.
02
Drugs
pemetrexed
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00055432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00055432.